TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Travere Therapeutics Inc (TVTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth, its declining net income and EPS, coupled with insider selling and weak technical indicators, suggest caution. The lack of recent positive news or significant trading signals further supports a hold recommendation.
The MACD is negative and expanding (-0.168), indicating bearish momentum. RSI is at 22.805, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 27.051), with resistance levels at 28.992 and 30.932. Overall, the technical indicators suggest a weak trend with no immediate bullish signals.
Analyst upgrades from Piper Sandler and BofA, with price targets raised to $38 and $44 respectively, indicate some long-term potential. Additionally, the FDA's consistent messaging on proteinuria as an approvable endpoint for FSGS is a positive development for the company.
Insider selling has increased significantly (125.53% over the last month), which may indicate a lack of confidence from those within the company. No recent news or significant hedge fund activity has been observed. Technical indicators are weak, and the stock has a higher probability of declining in the short term.
In Q4 2025, revenue grew by 73.41% YoY to $129.69M, showing strong top-line growth. However, net income dropped by -104.53% YoY to $2.73M, and EPS declined by -104.17% YoY to $0.03, reflecting poor profitability. Gross margin improved slightly to 98.03%, up 1.49% YoY.
Analysts have mixed views. Piper Sandler maintains a Neutral rating with a price target of $38, while BofA has a Buy rating with a price target of $44. Cantor Fitzgerald is Overweight on the stock, citing positive FDA developments. However, the lack of significant catalysts in the near term tempers enthusiasm.
